23 September 2020 | News
B-Temia Asia obtains Taiwan Food & Drug Administration (TFDA) product license
Image credit- keeogo.com
B-Temia Asia, a joint venture company between Wistron Medical Technology Company and Canadian robotics tech company B-Temia Inc., incorporated in November 2019, announces that it has obtained the Taiwanese Food and Drug Administration (TFDA) product license for its powered human mobility device KeeogoTM.
This license opens a new market and allows the company to commercialize KeeogoTM in Taiwan, which represents one of the most important markets of the Asian territory. Last week, B-Temia Inc. obtained its 510(k) Clearance from the American Food and Drug Administration (FDA) as well as the CE Mark in December last year.
KeeogoTM, short for "Keep on going", is a powered mobility device for lower limbs developed by B-Temia. Based on the B-Temia's proprietary DermoskeletonTM technology, KeeogoTM is a lightweight exoskeleton that detects, responds and supports an individual's movements with advanced software and motorized assistance, providing a true human- machine interface based on the individual needs.
KeeogoTM provides complementary knee strength and movement cues to assist trained healthcare professionals in rehabilitation and training of walking gait, sit-to-stand and stand- to-sit, squatting and stair climbing (ascent and descent).